Document:

License Agreement Amendment No. 1

 Exhibit 10.8 
 LICENSE AGREEMENT 
 AMENDMENT NO. 1 

May 3, 2007 
 THIS
AMENDMENT No. 1, dated as of the date shown above, is entered into by and between WAKE FOREST UNIVERSITY HEALTH SCIENCES, a North Carolina educational institution (“WFUHS”) and TENGION, INC., a Delaware corporation
(“Tengion”), for the purpose of amending the License Agreement dated as of January 1, 2006 between the parties (the “License Agreement”). 
 The parties agree that the License Agreement is hereby amended as follows: 
  

	 	1.	All capitalized terms not specifically defined herein have the definitions given them in the License Agreement. 

  

	 	2.	The contents of Article 1.10 of the License Agreement (definition of Deferred Invention) are deleted and the following is inserted in their place:
“[Reserved.]” 

  

	 	3.	The contents of Article 1.37 of the License Agreement (definition of Option Period) are deleted and the following is inserted in their place: “[Reserved.]”

  

	 	4.	Article 1.57 of the License Agreement is amended by inserting the words “or New Development Patents” immediately after the words “Improvement
Patents” where such words appear in each of clauses (i), (ii) and (iii) thereof. 

  

	 	5.	A new Article 1.59 is added to the License Agreement to read as follows: 

 1.59 “New Development Product” means any product, process or use thereof (i) which is covered by a Valid Claim
contained in any of the New Development Patents in the country in which the product, process or use thereof is made, used, sold, imported, offered for sale or transferred; (ii) which is developed, produced or manufactured using a process or
product which is covered by a Valid Claim contained in any of the New Development Patents in the country in which the product, process or use thereof is made, used, sold, imported, offered for sale or transferred; or (iii) the use of which is
covered by a Valid Claim contained in any of the New Development Patents in the country in which the product, process or use thereof is made, used, sold, imported, offered for sale or transferred. 
  

	 	6.	A new Article 1.60 is added to the License Agreement to read as follows: 

 1.60 “Handoff Date” means the date when Tengion initiates the first animal study conducted under Good Laboratory
Practices (“GLP”) for a specific New Development Product. For the purpose of clarity, the Handoff Date is intended to signify the date where WFUHS has essentially completed the discovery and pre-GLP portions of the work related to a New
Development Product, which work shall include sufficient data (in-vitro and in-vivo) to permit Tengion to conduct a GLP study for such New Development Product. 
  

					
	 *  Confidential Treatment Requested
	  		  	

	 	7.	A new Article 1.61 is added to the License Agreement to read as follows: 

 1.61 “Minimum Annual New Development Funding” shall have the meaning given it in Article 5.3 hereof. 
  

	 	8.	Article 2.1 of the License Agreement is amended by inserting the following clause to the end of such Article: “and to make, use and sell the New Development
Products under WFUHS’s rights in the New Development Patents in the Licensed Field only. 

  

	 	9.	The contents of Article 2.3 of the License Agreement are deleted and the following is inserted in their place: “[Reserved.]” 

  

	 	10.	Article 3.4.2 of the License Agreement is amended by deleting the words “Article 1.34” from Clause (c) of the first sentence and inserting the words
“Article 1.59” in their place. 

  

	 	11.	Article 3.8 of the License Agreement is amended as follows: 

  

	 	a.	The lead-in clause prior to Subparagraph 3.8.1 is amended by adding the words “or New Development Product” after the words “Improvement Product” in
the two places where they appear. 

  

	 	b.	The following sentence is added to the end of Subparagraph 3.8.3: 

 Moreover, if Tengion is paying two royalties to non-Affiliate third parties *. 
  

	 	12.	Article 3.10.1 of the License Agreement is amended to delete the words “Improvement Patent” in the third line thereof and to insert in their place the words
“WFUHS Patent Rights.” 

  

	 	13.	Article 3.11 of the License Agreement is amended as follows: 

  

	 	a.	The words “or New Development Patents” are inserted immediately after the words “Improvement Patents” in the second sentence thereof.

  

	 	b.	The word “or” immediately prior to the number “3.7” in the third sentence of Article 3.11 is replaced by a comma and the words “or 3.13”
are inserted immediately after the number “3.7” in the same sentence. 

  

	 	c.	A new sentence is added to the end of Article 3.11 as follows: 

 By way of further example, if at a particular time a kidney product falls within the provisions of both Article 3.4.1(c) (because it is a CHB Product

  

					
	 *  Confidential Treatment Requested
	  	2	  	

 
within Kidney Tissue) and Article 3.13 (because it is a New Development Product), then the applicable royalty rate at that time will be that prescribed by Article 3.13 (either * or *, depending
on aggregate annual Net Sales of New Development Products) because it is higher than the rate prescribed by Article 3.4.1 (c) *. 
  

	 	14.	Article 3.12 is hereby amended by inserting the words “or New Development Patent” immediately after the words “Improvement Patent” in the two places
such words appear in the lead-in clause prior to Subparagraph 3.12.1. 

  

	 	15.	A new Article 3.13 is added to the License Agreement to read as follows: 

 3.13 In partial consideration for the right and license granted under this Agreement, the transfer of the Know-How and the
execution of the Research Agreement, Tengion will pay to WFUHS *. For the purposes of this Article 3.13, “annual” Net Sales will be Net Sales recognized between January 1 and December 31 of any given year. 
  

	 	16.	A new Article 5.3 is hereby added to the License Agreement which reads as follows: 

 5.3 Tengion will promptly provide written notice to WFUHS when the Handoff Date is achieved for any New Development Product.

  

	 	17.	A new Article 5.4 is hereby added to the License Agreement which reads as follows: 

 5.4 Tengion may elect to provide funding to support development of New Development Products in the labs at WFIRM in
accordance with this Article 5.4. 
  

	 	5.4.1	In order to effectuate the provisions under this Agreement related to New Development Patents, the minimum funding to be provided by Tengion under this Article 5.4
shall be $1,000,000 (One Million Dollars) per calendar year. (“Minimum Annual New Development Funding”). 

  

	 	5.4.2	Tengion, in its sole discretion (but in accordance with the Annual Research Plan process contemplated under the Research Agreement), shall designate the Subfield(s) and
program(s) that are to be funded pursuant to this Article 5.4. 

  

	 	5.4.3	 Tengion, in its sole discretion (but in accordance with the Annual Research Plan process contemplated under the Research Agreement), may reduce the
Minimum Annual New Development Funding in increments of Two Hundred Thousand Dollars ($200,000). For each such increment by which the Minimum Annual New

  

					
	 *  Confidential Treatment Requested
	  	3	  	

	 	 
Development Funding is reduced, the license granted to Tengion under Article 2.1 hereof with respect to New Development Products shall be terminated with respect to one Subfield for New
Development Patents covering inventions arising after the effective date of such reduction in funding, provided that the diligence provisions of this License Agreement will still apply to inventions arising before the effective date of such
reduction in funding. Tengion will designate the Subfield as to which such termination is to take effect as follows: at the time Tengion notifies WFUHS that it has elected to reduce the Minimum Annual New Development Funding, it shall also notify
WFUHS which Subfield or Subfields, as the case may be, as to which the license for New Development Products is to be terminated. 

  

	 	5.4.4	After a Handoff Date for a particular New Development Product has occurred and Tengion is continuing to pursue the development of that New Development Product, Tengion
shall be relieved of the obligation to fund work at WFIRM in the Subfield of that New Development Product. This means that Tengion shall be permitted, at Tengion’s option, to reduce the Minimum Annual New Development Funding by an increment of
Two Hundred Thousand Dollars ($200,000) without having any part of the license granted under Article 2.1 with respect to New Development Products terminated. If Tengion reduces the Minimum Annual New Development Funding under this Article 5.4 it
will still be entitled to direct the remaining funding in accordance with Article 5.4. 

  

	 	18.	A new Article 5.5 is hereby added to the License Agreement which reads as follows: 

  

	 	5.5	In addition to the other diligence requirements of this Agreement, Tengion, its Affiliates or their respective Sublicensees will achieve the following milestones by the
following dates for each specific New Development Product: 

  

	 	5.5.1	Initiate the first human clinical trial (the “Clinical Trial”) within * after the Handoff Date; and 

  

	 	5.5.2	Apply for marketing approval to the United States Food and Drug Administration within * after the Handoff Date; and 

  

	 	5.5.3	Achieve first commercial sale in the United States within * after the Handoff Date. 

  

					
	 *  Confidential Treatment Requested
	  	4	  	

	 	5.5.4	Tengion will provide written notice to WFUHS of its achievement of the milestones in this Article 5.5 

  

	 	5.5.5	The milestones in this Article 5.5 and the payments in Article 5.6 will apply only to the first New Development Product in each Subfield. By way of example, although
two New Development Products in two different Subfields will have different Handoff Dates, they would both be required to meet the milestones of this Article 5.5 based upon their respective Handoff Dates. 

  

	 	5.5.6	Subject to the provisions of Article 5.5.9, If Tengion does not meet a milestone under this Article 5.5 for a particular New Development Product, WFUHS may, at its sole
option, terminate the license granted under Article 2.1 with respect to such New Development Product (and the corresponding New Development Patents). Such termination shall be effectuated by written notice to Tengion stating clearly the basis for
the termination and the New Development Product as to which such termination applies. If Tengion provides both payments under Section 5.6 below, the provision of Article 5.5.1 shall be deemed satisfied. 

  

	 	5.5.7	For the purpose of clarity, the intent on the part of WFUHS in Article 5.5.6 is to regain the ability to independently develop a New Development Product which Tengion
is neither funding in the WFIRM labs nor successfully developing at Tengion (whether with or without collaboration with sublicensees). Article 5.5.6 is not intended to limit the collaboration between WFUHS and Tengion on future New Development
Products in any Subfield (i.e. if the first collaborative attempt in a Subfield proves impracticable from Tengion’s perspective, collaboration would still be possible with later attempts). 

  

	 	5.5.8	Any limitation of the license granted under this Agreement, as anticipated under Article 5.5.6, will not affect the other terms of this Agreement, financial or
otherwise, in any way. 

  

	 	5.5.9	 Notwithstanding the provisions of Articles 5.5.1 - 5.5.3 and 5.5.6, mere failure by Tengion to satisfy a date-based milestone set forth in Article
5.5.1 - 5.5.3, shall not, in itself, give WFUHS the right to terminate the license with respect to the New Development Product in question if Tengion can demonstrate by clear and convincing evidence

  

					
	 *  Confidential Treatment Requested
	  	5	  	

	 	 
and relative to customary product development standards in the biotechnology industry that it is otherwise exercising commercially reasonable diligent efforts toward the development and
commercialization of the New Development Product in question. For clarity, the purpose of this Article 5.5.9 is to prevent an unfair forfeiture of Tengion’s license in a case where, for example, Tengion has expended substantial and appropriate
resources on the clinical development of a New Development Product and the first commercial sale milestone is nonetheless not met by virtue of patient enrollment difficulties or an extended FDA review process caused by factors that were not
reasonably within Tengion’s sole control. 

  

	 	19.	A new Article 5.6 is hereby added reading as follows: 

 5.6 
  

	 	5.6.1	In addition to the other diligence provisions, Tengion will pay to WFUHS license maintenance fees as follows for each New Development Product: *

  

	 	5.6.2	Amounts paid to WFUHS under this Article 5.5 (i) and (ii) are creditable against royalties payable to WFUHS for future commercial sales of that particular New
Development Product. 

  

	 	20.	A new Article 5.7 is hereby added reading as follows: 

  

	 	5.7	Under certain circumstances, the license granted hereunder with respect to certain New Development Patents may be terminated on a Subfield-by-Subfield basis at the
election of either WFUHS or Tengion as set forth in this Article 5.7. 

  

	 	5.7.1	The intent of this Article 5.7 is to permit WFUHS to regain control of New Development Patents that are not being practiced by Tengion and do not provide intellectual
property protection around any New Development Product being developed or commercialized by Tengion. 

  

	 	5.7.2	The parties recognize that during the course of pre-clinical development, there may be significant ambiguity concerning identifying specific patents in a portfolio of
patents that are relevant to a particular product candidate. The parties also believe that when a product reaches the stage of marketing approval, substantially more clarity will necessarily exist regarding the patents that provide the intellectual
property basis for robust commercialization of such product. 

  

					
	 *  Confidential Treatment Requested
	  	6	  	

 5.7.2.1 Promptly upon issuance of any New Development Patent, Tengion will submit to WFUHS
a brief, written, good-faith plan for the commercialization of the claimed subject matter of such New Development Patent. 
  

	 	5.7.3	Tengion is to receive the benefit of the doubt during the pre-clinical and clinical development stages of a particular New Development Product regarding identifying New
Development Patents that are required for robust commercialization of such product. During the pre-clinical and clinical development of a particular New Development Product in a given Subfield, if the diligence requirements set forth in this
Agreement are satisfied for such New Development Product, then such diligence requirements will be deemed to be satisfied for all New Development Patents in such Subfield. 

  

	 	5.7.4	Within sixty (60) days after receipt of marketing approval by the FDA of a particular New Development Product, Tengion will provide a written certification to
WFUHS identifying which New Development Patents in that product’s Subfield are necessary for the robust commercialization of such product. Subject to Article 5.7.5, Tengion shall be deemed to be out of compliance with its diligence obligations
set forth in Article 5.5 hereof with respect to any New Development Patent in that product’s Subfield that are not so identified and Article 5.5.6 shall, therefore, apply to any such New Development Patent. In addition, upon the * of the
issuance of any New Development Patent, Tengion will report to WFUHS which product or product candidate requires that particular New Development Patent for its robust commercialization. 

  

	 	5.7.5	Notwithstanding the provisions of Article 5.7.4 hereof, Tengion shall not be deemed to be out of compliance with its diligence obligations described in Article 5.5 with
respect to any New Development Patent that, at the time of the notice described in Article 5.7.4, is required for the robust commercialization of a different New Development Product as to which Tengion is then separately satisfying such diligence
obligations. 

  

					
	 *  Confidential Treatment Requested
	  	7	  	

	 	21.	Article 6.2 is amended as follows: 

  

	 	a.	The last sentence of Subparagraph 6.2.8 is deleted and the following sentence is inserted in its place: 

 If Tengion does provide to OTAM an Objection Letter for a particular SRA Invention, the classification of such SRA Invention as the basis
for an Improvement Patent or a New Development Patent will be determined in accordance with the ADR provisions set forth in Article 18. 
  

	 	b.	The contents of each of Subparagraphs 6.2.9 through 6.2.11 are deleted and the following is inserted in their place: “[Reserved.]” 

 

	 	22.	The contents of Article 7 are deleted and the following is inserted in their place: “[Reserved.]” 

  

	 	23.	Tengion’s street address for notice (and for the copy of the notice) is changed to 2900 Potshop Lane, Suite 100, East Norriton, Pennsylvania 19403. The other
aspects of the address for notice remain the same. 

 Except as set forth above, all provisions of the License Agreement remain in
full force and effect. This Amendment No. 1 may be executed in two or more counterparts, each of which will be deemed an original, but all of which taken together will constitute one and the same instrument. 
 [Signatures on next page.] 
  

					
	 *  Confidential Treatment Requested
	  	8	  	

 IN WITNESS WHEREOF, the parties have caused this License Agreement Amendment No. 1 to be executed as of
the date first set forth above by their duly authorized representatives. 
  

									
	 WAKE FOREST UNIVERSITY
 HEALTH SCIENCES
	 		 	TENGION, INC.
					
	BY:	 	/s/ Michael A. Batalia	 		 	BY:	 	/s/ Steven A. Nichtberger
		 	 Michael A. Batalia, Ph.D.
 Director, Technology
 Asset Management
	 		 		 	 Steven A. Nichtberger, M.D.
 President and CEO

  

					
	 *  Confidential Treatment Requested
	  	9Form of Indemnification Agreement

 Exhibit 10.33 
 INDEMNIFICATION AGREEMENT 
 This Indemnification
Agreement (the “Agreement”) is made and entered into this [    ] day of [            ] 2010, by and between Tengion, Inc., a Delaware corporation
(the “Company”), and [NAME] (“Indemnitee”). 
 W I T N E S S
E T H: 
 WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations
as directors, officers, employees, agents, fiduciaries and related parties unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of
their service to and activities on behalf of the corporation. 
 WHEREAS, in recognition of Indemnitee’s need for
substantial protection against personal liability in order to enhance Indemnitee’s continued service to the Company in an effective manner and Indemnitee’s reliance on the provisions of the Company’s Certificate of Incorporation
(“Certificate of Incorporation”) and the Company’s Bylaws (the “Bylaws”) requiring indemnification of the Indemnitee to the fullest extent permitted by law, and in part to provide Indemnitee with specific contractual
assurance that the protection promised by such Certificate of Incorporation and Bylaws will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of such Certificate of Incorporation or Bylaws or any change in
the composition of the Company’s Board of Directors or acquisition transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification of and the advancing of expenses to Indemnitee to the fullest
extent (whether partial or complete) permitted by law and as set forth in this Agreement. 
 WHEREAS, the Certificate of
Incorporation, the Bylaws and the General Corporation Law of the State of Delaware (“DGCL”) expressly provide that the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered
into between the Company and members of the board of directors, officers and other persons with respect to indemnification. 
 WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or
continue to serve the Company free from undue concern that they will not be so indemnified. 
 WHEREAS, this Agreement is a
supplement to and in furtherance of the Certificate of Incorporation and Bylaws and any resolutions adopted pursuant thereto and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. 

 NOW, THEREFORE, in consideration of the premises and of Indemnitee continuing to serve the
Company directly or, at its request, with another enterprise, and intending to be legally bound hereby, the parties hereto agree as follows: 
 Section 1. Basic Indemnification Agreement. (a) In the event Indemnitee was, is or becomes a party to or witness or other participant in, or is threatened to be made a party
to or witness or other participant in, a Claim (as defined in Section 10(b) herein) by reason of (or arising in part out of) an Indemnifiable Event (as defined in Section 10(d) herein), the Company shall indemnify Indemnitee to the fullest
extent permitted by law as soon as practicable but in any event no later than thirty (30) days after written demand is presented to the Company, against any and all Expenses (as defined in Section 10(c) herein), judgments, fines, penalties
and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection therewith) of such Claim actually and reasonably incurred by or on behalf of Indemnitee in connection with such Claim and any
federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement. If requested by Indemnitee in writing, the Company shall advance (within ten (10) business days of
such written request) any and all Expenses to Indemnitee (an “Expense Advance”). Notwithstanding anything in this Agreement to the contrary, and except as provided in Section 3, prior to a Change of Control (as defined in
Section 10(a) herein), Indemnitee shall not be entitled to indemnification pursuant to this Agreement in connection with any Claim (i) initiated by Indemnitee against the Company or any director or officer of the Company unless the Company
has joined in or consented to the initiation of such Claim; or (ii) made on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its stockholders or is an act or omission not in
good faith or which involves intentional misconduct or a knowing violation of the law; or (iii) arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). 
 (b) Notwithstanding the foregoing, (i) the indemnification obligations of the Company
under Section 1(a) shall be subject to the condition that the Reviewing Party (as defined in Section 10(e) herein) shall not have determined (in a written opinion, in any case in which the special independent counsel referred to in
Section 2 hereof is involved) that Indemnitee would not be permitted to be indemnified under applicable law, and (ii) the obligation of the Company to make an Expense Advance pursuant to Section 1(a) shall be subject to the condition
that the Company receives an undertaking that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by
Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced legal proceedings in the Court of Chancery of the State of Delaware (the “Delaware Court”)
to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee
shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s obligation to
reimburse the Company for Expense Advances shall be unsecured and no interest shall be charged thereon. If there has not been a Change in Control, the Reviewing Party shall be selected by the Board of Directors, and if there has been such a Change
in Control, the Reviewing Party shall be the special independent counsel referred to in Section 2 hereof. If there has been no determination by the Reviewing Party or if the Reviewing Party determines that Indemnitee substantively would not

  

 2 

 
be permitted to be indemnified in whole or in part under applicable law, Indemnitee shall have the right to commence litigation in the Delaware Court seeking an initial determination by the court
or challenging any such determination by the Reviewing Party or any aspect thereof and the Company hereby consents to service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive and
binding on the Company and Indemnitee. 
 Section 2. Change in Control. The Company agrees that if there
is a Change in Control of the Company (other than a Change in Control which has been approved by two- thirds or more of the Company’s Board of Directors who were directors immediately prior to such Change in Control) then with respect to all
matters thereafter arising concerning the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims for
Indemnifiable Events, the Company shall seek legal advice only from special independent counsel selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld or delayed) and who has not otherwise performed
services for the Company within the last five years (other than in connection with such matters) or for Indemnitee. In the event that Indemnitee and the Company are unable to agree on the selection of the special independent counsel, such special
independent counsel shall be selected by lot from among at least five law firms with offices in the State of Delaware having more than fifty attorneys, having a rating of “av” or better in the then current Martindale Hubbell Law Directory
and having attorneys which specialize in corporate law. Such selection shall be made in the presence of Indemnitee (and his legal counsel or either of them, as Indemnitee may elect). Such counsel, among other things, shall, within ninety
(90) days of its retention, render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to pay the reasonable fees of the
special independent counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, and damages arising out of or relating to this Agreement or its engagement pursuant
hereto. 
 Section 3. Indemnification for Additional Expenses. The Company shall indemnify Indemnitee
against any and all expenses (including attorneys’ fees) and, if requested by Indemnitee in writing, shall (within ten (10) business days of such written request) advance such expenses to Indemnitee, which are incurred by Indemnitee in
connection with any Claim asserted against or action brought by Indemnitee for (i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or
hereafter in effect relating to Claims for Indemnifiable Events and/or (ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined
to be entitled to such indemnification, advance expense payment or insurance recovery, as the case may be. The Indemnitee shall qualify for advances solely upon the execution and delivery to the Company of an undertaking providing that the
Indemnitee undertakes to repay the advance to the extent that it is ultimately determined that the Indemnitee is not entitled to be indemnified by the Company. 
  

 3 

 Section 4. Partial Indemnity, Etc. If Indemnitee is entitled under
any provisions of this Agreement to indemnification by the Company of some or a portion of the Expenses, liabilities, judgments, fines, penalties and amounts paid in settlement of a Claim but not, however, for all of the total amount thereof, the
Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in
defense of any or all Claims relating in whole or in part to an Indemnifiable Event or in defense of any issue or matter therein, including dismissal without prejudice, Indemnitee shall be indemnified against all Expenses incurred in connection
therewith. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder the burden of proof shall be on the Company to establish that Indemnitee is not so entitled.

 Section 5. No Presumption. For purposes of this Agreement, the termination of any action, suit or
proceeding by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that Indemnitee did not meet any particular standard of conduct or
have any particular belief. 
 Section 6. Notification and Defense of Claim. Within thirty
(30) days after receipt by Indemnitee of notice of the commencement of a Claim which may involve an Indemnifiable Event, Indemnitee will, if a claim in respect thereof is to be made against the Company under this Agreement, submit to the
Company a written notice identifying the proceeding, but the omission so to notify the Company will not relieve it from any liability which it may have to Indemnitee under this Agreement unless the Company is materially prejudiced by such lack of
notice. With respect to any such Claim as to which Indemnitee notifies the Company of the commencement thereof: 
 (a) the
Company will be entitled to participate therein at its own expense; 
 (b) except as otherwise provided below, to the extent
that it may wish, the Company jointly with any other indemnifying party similarly notified will be entitled to assume the defense thereof, with counsel satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume
the defense thereof, the Company will not be liable to Indemnitee under this Agreement for any legal or other expenses subsequently incurred by Indemnitee in connection with the defense thereof other than reasonable costs of investigation or as
otherwise provided below. Indemnitee shall have the right to employ its own counsel in such action, suit or proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall
be at the expense of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Company, (ii) Indemnitee shall have reasonably concluded on the advice of counsel that there may be a conflict of interest
between the Company and the Indemnitee in the conduct of the defense of such action, or (iii) the Company shall not in fact have employed counsel to assume the defense of such action, in each of which cases the fees and expenses of counsel
shall be at the expense of the Company. The Company shall not be entitled to assume the defense of any claim brought by or on behalf of the Company or as to which Indemnitee shall have made the conclusion provided for in clause (ii) above; and

  

 4 

 (c) the Company shall not be liable to indemnify Indemnitee under this Agreement for any
amounts paid in settlement of any action or claim effected without its written consent. The Company shall not settle any action or claim in any manner that would impose any penalty or limitation on Indemnitee without Indemnitee’s written
consent. Neither the Company nor Indemnitee will unreasonably withhold or delay their consent to any proposed settlement. 
 Section 7. Priority of Indemnification. In the event that the Indemnitee has rights to indemnification/insurance provided by a third party (the “Third-Party Indemnitors”), then the Company hereby agrees
(i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Third-Party Indemnitors to advance Expenses or to provide indemnification for the same Expenses or liabilities incurred by
Indemnitee are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the
extent legally permitted and as required by the terms of this Agreement and the Certificate of Incorporation or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the
Third-Party Indemnitors and (iii) that it irrevocably waives, relinquishes and releases the Third-Party Indemnitors from any and all claims against the Third-Party Indemnitors for contribution, subrogation or any other recovery of any kind in
respect thereof. The Company further agrees that no advancement or payment by the Third-Party Indemnitors on behalf of Indemnitee with respect to any Claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing
and the Third-Party Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the
Third-Party Indemnitors are express third party beneficiaries of the terms of this Section 7. 
 Section 8.
Non-exclusivity, Etc. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the Certificate of Incorporation, the Bylaws, the DGCL, any agreement, a vote of the stockholders, a resolution
of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee acting on
behalf of the Company and at the request of the Company prior to such amendment, alteration or repeal. To the extent that a change in the DGCL (whether by statute or judicial decision), the Certificate of Incorporation or the Bylaws permits greater
indemnification by agreement than would be afforded currently under the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so
afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or
hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 
 Section 9. Liability Insurance. To the extent the Company maintains an insurance policy or policies providing
directors’ and officers’ liability insurance, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any Company director or officer. If, at the time
the

  

 5 

 
Company receives notice from any source of a Claim as to which Indemnitee is a party or a participant (as a witness or otherwise), the Company has director and officer liability insurance in
effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to
pay, on behalf of the Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such policies. 
 Section 10. Certain Definitions. 
 (a) Change in Control: shall be deemed to have occurred if:

 (i) any person, as that term is used in Section 13(d) and Section 14(d)(2) of the Exchange Act, becomes, is
discovered to be, or files a report on Schedule 13D or 14D-1 (or any successor schedule, form or report) disclosing that such person is a beneficial owner (as defined in Rule 13d-3 under the Exchange Act or any successor rule or
regulation), directly or indirectly, of securities of the Company representing 20% or more of the total voting power of the Company’s then outstanding Voting Securities (as defined in Section 10(f) herein); 
 (ii) individuals who, as of the date hereof, constitute the Board of Directors of the Company cease for any reason to constitute at least a
majority of the Board of Directors of the Company, unless any such change is approved by a unanimous vote of the members of the Board of Directors of the Company in office immediately prior to such cessation; 
 (iii) the Company, or any material subsidiary of the Company, is merged, consolidated or reorganized into or with another corporation or
other legal person (an “Acquiring Person”) or securities of the Company are exchanged for securities of an Acquiring Person, and immediately after such merger, consolidation, reorganization or exchange less than a majority of the combined
voting power of the then outstanding securities of the Acquiring Person immediately after such transaction are held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such transaction; 
 (iv) the Company, or any material subsidiary of the Company, in any transaction or series of related transactions, sells or otherwise
transfers all or substantially all of the assets of the Company and its subsidiaries taken as a whole to an Acquiring Person, and less than a majority of the combined voting power of the then outstanding securities of the Acquiring Person
immediately after such sale or transfer is held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such sale or transfer; 
 (v) the Company and its subsidiaries, in any transaction or series of related transactions, sells or otherwise transfers business operations that generated two thirds or more of the consolidated revenues
(determined on the basis of the Company’s four most recently completed fiscal quarters) of the Company and its subsidiaries immediately prior thereto; 
 (vi) the Company files a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing that a change in control of the Company has or may have occurred or
will or may occur in the future pursuant to any then existing contract or transaction; or 
  

 6 

 (vii) any other transaction or series of related transactions occur that have substantially
the effect of the transactions specified in any of the preceding clauses in this paragraph (a). 
 Notwithstanding the
provisions of Section 10(a)(i) or 10(a)(iv), unless otherwise determined in a specific case by majority vote of the Board of Directors of the Company, a Change of Control shall not be deemed to have occurred for purposes of this Agreement
solely because (i) the Company, (ii) an entity in which the Company directly or indirectly beneficially owns 50% or more of the voting securities or (iii) any Company sponsored employee stock ownership plan, or any other employee
benefit plan of the Company, either files or becomes obligated to file a report or a proxy statement under or in response to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor schedule, form or report or
item therein) under the Exchange Act, disclosing beneficial ownership by it of shares of stock of the Company, or because the Company reports that a Change in Control of the Company has or may have occurred or will or may occur in the future by
reason of such beneficial ownership. 
 (b) Claim: any threatened, pending or completed action, suit, proceeding or
alternative dispute resolution mechanism, or any inquiry, hearing or investigation whether conducted by the Company or any other party, whether civil, criminal, administrative, investigative or other. 
 (c) Expenses: include reasonable attorneys’ fees and all other reasonable costs, fees, expenses and obligations of any nature
whatsoever paid or incurred in connection with investigating, defending, being a witness in or participating in (including appeal), or preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event. 

(d) Indemnifiable Event: any event or occurrence (whether before or after the date hereof) related to the fact that Indemnitee is or
was a director, officer, employee, consultant, agent or fiduciary of or to the Company, or is or was serving at the request of the Board of Directors as a director, officer, employee, trustee, agent or fiduciary of another corporation, partnership,
joint venture, employee benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee in any such capacity. 
 (e) Reviewing Party: (i) the Company’s Board of Directors (provided that a majority of directors are not parties to the particular Claim for which Indemnitee is seeking indemnification) or
(ii) any other person or body appointed by the Company’s Board of Directors, who is not a party to the particular Claim for which Indemnitee is seeking indemnification, or (iii) if there has been a Change in Control, the special
independent counsel referred to in Section 2 hereof. 
 (f) Voting Securities: any securities of the Company which
vote generally in the election of directors. 
  

 7 

 Section 11. Amendments, Termination and Waiver. No supplement,
modification, amendment or termination of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 
 Section 12.
Entire Agreement. This Agreement constitutes the entire agreement between the Company and the Indemnitee pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof
(which shall not include the Certificate of Incorporation or the Bylaws) existing between the Company and the Indemnitee are expressly canceled. 
 Section 13. Subrogation. Except as provided in Section 7, in the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the
rights of recovery of Indemnitee (other than against the Third-Party Indemnitors), who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to
enable the Company effectively to bring suit to enforce such rights. 
 Section 14. No Duplication of
Payments. Except as provided in Section 7, the Company shall not be liable under this Agreement to make any payment in connection with any Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment
(under insurance policy, Certificate of Incorporation or otherwise) of the amounts otherwise indemnifiable hereunder. 
 Section 15. Binding Effect, Etc. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company, spouse, heirs, and personal and legal representatives. This Agreement shall continue in effect regardless of whether
Indemnitee continues to serve as a director or officer (or in one of the capacities enumerated in Section 10(d) hereof) of the Company or of any other enterprise at the Board of Director’s request. 
 Section 16. Severability. The provisions of this Agreement shall be severable in the event that any of the
provisions hereof (including any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable to the
fullest extent permitted by law. 
 Section 17. Applicable Law and Consent to Jurisdiction. This Agreement
and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and
unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in
any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware

  

 8 

 
Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, irrevocably, to the extent such party is not a resident of the State of
Delaware, Corporation Service Company, 2711 Centerville Road, City of Wilmington, County of New Castle, Delaware 19808 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such
action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the
Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 
 Section 18. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for
all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of
this Agreement. 
 [Signature Page Follows] 
  

 9 

 This Indemnification Agreement is effective as of the date first set forth above.

  

			
	TENGION, INC.
		
	By:	 	  

	Name	 	
	Title	 	
	
	INDEMNITEE:
	
	  

	[NAME OF INDEMNITEE]

  

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]